QDEL
QuidelOrtho Corporation
Set alert
- YTD
- -53.61%
- 1 year
- -50.58%
- Open
- 13.46
- Prev close
- 13.76
- Mkt cap
- 908.62M
- Vol
- 1.74M
- Avg vol
- 1.77M
- EPS
- -15.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.48
- High
- 13.51
- Forward P/E
- 10.22
- Beta
- 0.69
- Short ratio
- 10.38
- Inst. own
- 124.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 15.81
- 200-d avg
- 19.67
- 1y target
- 14.67
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 4.00B
- Trailing P/E
- 0.00
- Forward P/E
- 10.22
- PEG ratio
- 2.06
- Price / sales
- 0.38
- Price / book
- 0.57
- EPS (TTM)
- -15.43
- Beta
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -39.20%
- Revenue (TTM)
- 2.67B
- Revenue growth
- 2.80%
- Free cash flow
- 146.76M
- Total cash
- 123.40M
- Total debt
- 3.08B
- Return on equity
- -45.91%
- Shares outstanding
- 68.58M
- Short % of float
- 29.75%
- 50-day average
- 15.81
- 200-day average
- 19.67
Analyst view
Consensus: hold
- Target (low)
- 12.00
- Target (mean)
- 14.67
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.17953.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 28, 2026 | 0.18 | — | — | — |
| Aug 6, 2026 | Jun 28, 2026 | -0.04884 | 0.13 | +0.18 | +366.18% |
| May 5, 2026 | Mar 29, 2026 | 0.37 | -0.04 | -0.41 | -110.81% |
| Feb 11, 2026 | Dec 28, 2025 | 0.43 | 0.46 | +0.03 | +6.98% |
| Nov 5, 2025 | Sep 28, 2025 | 0.51 | 0.80 | +0.29 | +56.86% |
| Aug 5, 2025 | Jun 29, 2025 | 0.00153 | 0.12 | +0.12 | +7,743.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2026 | Citigroup | main | Neutral | Neutral |
| Jul 1, 2026 | JP Morgan | main | Underweight | Underweight |
| May 7, 2026 | Jefferies | down | Buy | Hold |
| May 6, 2026 | Citigroup | main | Neutral | Neutral |
| Apr 10, 2026 | UBS | main | Neutral | Neutral |
| Feb 12, 2026 | Citigroup | main | Neutral | Neutral |
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- quidelortho.com
News
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
- Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Reasons to Add QuidelOrtho Stock to Your Portfolio for Now
- QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript
- Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Contrasting QuidelOrtho (NASDAQ:QDEL) & Cooper Companies (NASDAQ:COO)
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
Your note
Sign in to keep a note on QDEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLASER BRIAN J | Chief Executive Officer | Conversion of Exercise of derivative security | May 14, 2026 | 75,722 |
| BUECHLER KENNETH F | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 110,906 |
| BUJARSKI ROBERT JOSEPH | Chief Operating Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 44,810 |
| BUSKY JOSEPH M | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 26, 2026 | 55,108 |
| HODGES MICHELLE A | Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 41,605 |
| MICHAEL EDWARD L | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 29,433 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.34% | 11,202,523 | 165.13M | Jun 29, 2026 |
| FMR, LLC | 10.74% | 7,363,696 | 108.54M | Jun 29, 2026 |
| Newtyn Management, Llc | 9.66% | 6,625,000 | 97.65M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.03% | 4,135,464 | 60.96M | Jun 29, 2026 |
| Neuberger Berman Group, LLC | 5.15% | 3,534,619 | 52.10M | Jun 29, 2026 |
| Invesco Ltd. | 5.07% | 3,473,432 | 51.20M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Capital Trust-Fidelity Value Fund | 6.38% | 4,371,779 | 64.44M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Small-Cap ETF | 6.06% | 4,153,277 | 61.22M | Jul 30, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 4.40% | 3,020,112 | 44.52M | Apr 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 4.14% | 2,836,050 | 41.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,172,676 | 32.03M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,796,239 | 26.48M | Jun 29, 2026 |